• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

Recent Advances in the Study of 2-(Azetidin-1-yl)-5-bromopyrimidine-4-carboxylic acid (CAS: 1780970-29-7)

The compound 2-(Azetidin-1-yl)-5-bromopyrimidine-4-carboxylic acid (CAS: 1780970-29-7) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This heterocyclic compound, featuring a pyrimidine core substituted with an azetidine ring and a bromine atom, exhibits unique physicochemical properties that make it a promising scaffold for the design of novel therapeutic agents. Recent studies have explored its utility as a key intermediate in the synthesis of bioactive molecules targeting various diseases, including cancer, infectious diseases, and neurological disorders.

One of the most notable advancements in the study of this compound is its role in the development of kinase inhibitors. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is implicated in numerous pathological conditions. Researchers have demonstrated that derivatives of 2-(Azetidin-1-yl)-5-bromopyrimidine-4-carboxylic acid can be tailored to selectively inhibit specific kinases, thereby offering a potential therapeutic strategy for cancer treatment. For instance, a recent study published in the Journal of Medicinal Chemistry highlighted the compound's efficacy in inhibiting the activity of certain tyrosine kinases, which are often overexpressed in malignant cells.

In addition to its applications in oncology, this compound has also been investigated for its antimicrobial properties. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported that structural modifications of 2-(Azetidin-1-yl)-5-bromopyrimidine-4-carboxylic acid yielded derivatives with potent activity against drug-resistant bacterial strains. The presence of the bromine atom and the azetidine ring was found to enhance the compound's ability to penetrate bacterial cell membranes, making it a valuable candidate for further development as an antibiotic.

Another area of interest is the compound's potential in central nervous system (CNS) drug discovery. The azetidine moiety, known for its favorable pharmacokinetic properties, has been leveraged to improve blood-brain barrier penetration. Recent preclinical studies have shown that derivatives of 2-(Azetidin-1-yl)-5-bromopyrimidine-4-carboxylic acid exhibit promising activity in modulating neurotransmitter receptors, suggesting their potential utility in treating neurological disorders such as Alzheimer's disease and schizophrenia.

The synthesis and characterization of 2-(Azetidin-1-yl)-5-bromopyrimidine-4-carboxylic acid have also been refined in recent years. Advanced techniques such as high-throughput screening and computational modeling have been employed to optimize its synthetic routes and improve yield. A 2022 publication in Organic Process Research & Development detailed a scalable and cost-effective method for producing this compound, which is crucial for its broader application in pharmaceutical research.

In conclusion, 2-(Azetidin-1-yl)-5-bromopyrimidine-4-carboxylic acid (CAS: 1780970-29-7) represents a versatile and promising scaffold in medicinal chemistry. Its applications span multiple therapeutic areas, and ongoing research continues to uncover new opportunities for its use. As the field advances, further studies are expected to elucidate its full potential and pave the way for the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)